Upstate Active Clinical Trials

Study Title:

D419ML00003 - A Phase IIIb, Randomized, Multicenter, Open-label Study to assess the Efficacy of Durvalumab plus Tremelimumab versus Pembrolizumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Non-Squamous Histology who have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS (TRITON)

What is the purpose of the study? (in Layman's terms, please describe the study)

A Study to Investigate the Efficacy of Durvalumab plus Tremelimumab in
Combination with Chemotherapy compared with Pembrolizumab in Combination with
Chemotherapy in metastatic NSCLC Patients with Non-squamous Histology who have
Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Upstate Institutional Review Board (IRB) Number:

2183966

Study/Protocol ID:

D419ML00003

Study Phase:

A Phase IIIb,

Patient Age Group:

Adults

Principal Investigator:

Stephen L Graziano, MD

Who is eligible?

Histologically or cytologically documented Stage IV non-squamous NSCLC not
amenable to curative surgery or radiation. Participants must have tumors with STK11 or KEAP1 or KRAS mutations. Co-mutations

What is involved if I participate?

• How long is the study?
  10Y
• Is transportation provided or reimbursed?
  Yes
• Is parking provided or reimbursed?
  No
• What tests and procedures are involved?
  Labs/ scans/ genetic testing

Where will the study take place?

Upstate Cancer center/ Community/ Verona/ Oswego

Other Information:

None

Who can I contact for more information?

Name: Raneem Alarawi
Phone: 315-464-6074
Email: [email protected]

Return to Previous Page || Search Again